Vegzelma (Bevacizumab-Adcd) Patent Expiration, LOE Window & CMS Spending

Vegzelma (Bevacizumab-Adcd) by Celltrion: Biologic BLA (Purple Book Regime), 0 AB generics, $11.1M 2024 CMS Part D & Medicaid spend, and $2,710 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorCelltrion
FDA Application & PathwayB761268 (BLA)
Exclusivity / Cliff HorizonBiologic BLA (Purple Book Regime)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$11.1M
2024 Medicare Part D Spend$265K
2024 Medicaid Spend$10.8M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($2,710 intro WAC)